Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naive to PDE5 Inhibitors.

Trial Profile

Impact of Tadalafil (LY450190) Once a Day or Tadalafil on Demand Compared to Sildenafil Citrate on Demand on Treatment Discontinuation in Patients With Erectile Dysfunction Who Are naive to PDE5 Inhibitors.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2014

At a glance

  • Drugs Sildenafil (Primary) ; Tadalafil (Primary)
  • Indications Erectile dysfunction
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register: DRKS00004040).
    • 18 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 18 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top